



Atty. Docket No.: 1111/1220

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Segal, Andrew
Serial No.: 09/345,148
Filed: June 30, 1999
Entitled: CD40 Ligand-Enhanced Cells
and Methods of Modulating an
Immune Response to an
Antigen

Examiner: Gambel, P.

Group Art Unit: 1651

64B
69
47B-07

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Box: Commissioner for Patents, Washington, D.C. 20231.

Kathleen M. Williams, Ph.D

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
Washington, D.C. 20231

**RESPONSE TO RESTRICTION REQUIREMENT AND
PRELIMINARY AMENDMENT**

In response to the Restriction Requirement dated November 27, 2000, Applicants elect **Group I, Claims 1-15, 28, 29** for prosecution on the merits, with traverse.

We elect the species lipid-linked CD40-specific antibody.

Please add new claims 69-70 as follows:

69. The method of claim 1, wherein said CD40 ligand-enhanced cell is a pathogenic cell.

70. The method of claim 69, wherein said vaccine composition further comprises an opsonin-enhanced pathogenic cell, wherein said opsonin of said opsonin pathogenic cell is selected from the group consisting of mannose binding protein and the alpha' chain of C3b.

B1
Sub
ct

Respectfully submitted,

Date: 4/3/01

Name: Kathleen M. Williams
Registration No.: 34,380
Palmer & Dodge LLP
One Beacon Street
Boston, MA 02108
Tel: 617-573-0100

We elect the species lipid-linked CD40-specific antibody.

Please add new claims 69-70 as follows:

69. The method of claim 1, wherein said CD40 ligand-enhanced cell is a pathogenic cell.

70. The method of claim 69, wherein said vaccine composition further comprises an opsonin-enhanced pathogenic cell, wherein said opsonin of said opsonin pathogenic cell is selected from the group consisting of mannose binding protein and the alpha' chain of C3b.